A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01196247

Enrollment

Registered

2010-09-08

Start date

2010-09-30

Completion date

2012-02-29

Last updated

2012-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously Treated Metastatic Pancreatic Cancer

Keywords

pancreatic cancer, molecular profiling, SU2C, Second line therapy, Stage 4

Brief summary

The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.

Detailed description

Following first-line therapy with a gemcitabine based regimen, a significant number of patients will maintain an adequate performance status and be able to tolerate a second-line therapy. A recent phase III trial randomized patients to either 5-flurouracil (5FU), folinic acid or to the addition of weekly oxaliplatin to the same regimen of 5FU/folinic acid. The interim results showed a statistically significant survival advantage for the oxaliplatin containing arm (26 versus 13 weeks, P= 0.014). However the outcome of patients who have progressed on a first-line gemcitabine regimen is still poor with median survival of about 2-6 months. Almost all patients with advanced APC, treated with gemcitabine alone or a gemcitabine based combination therapy will exhibit resistance to therapy. In patients treated with gemcitabine alone, the time to progression (TTP) is about 3-4 months. Thus most patients will exhibit progression and /or toxicity and will require second line therapy at 4-6 months into first line therapy. The best one year survival reported in a phase II trial is only 24%. However there is no standard second line therapy for APC, a rapid progression of tumor is seen in this setting, and new strategies based on rational target identification are needed. In this study we propose to select therapy based on the molecular profiling of each patients tumor.

Interventions

DRUGDrug will be recommended based on IHC/Fish, CGH and Pan-XenoBank

FDA approved drugs as indicated by molecular profiling

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* metastatic adenocarcinoma of the pancreas * male or non-pregnant female * 18 years of age or greater * one prior therapy for the treatment of metastatic disease * must start continuation therapy within 9 months of starting first line treatment * have adequate organ and bone marrow function * must have a Karnofsky performance status greater than or equal to 70 * one or more metastatic tumors measurable by CT scan and accessible for biopsy

Exclusion criteria

* operable or locally advanced pancreatic cancer * metastatic tumor that is not amendable to biopsy * known brain mets unless previously treated and well controlled * active, uncontrolled bacterial, viral or fungal infections * known infection with HIV, hepatitis B or hepatitis C * pregnant or breast-feeding patients

Design outcomes

Primary

Measure	Time frame	Description
Determine the percent of patients who are alive at one year	One year	Goal is to improve the one year survival (from start of first-line therapy for metastatic disease) to 60%

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026